At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
INCB054707drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating INCB054707 for Hidradenitis Suppurativa. Completed, enrolled 10 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionApr 2019
TodayJul 2026
First PostedJun 26, 2018
Enrollment StartJul 17, 2018
Primary CompletionApr 22, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.0 years ago
Interventions
INCB054707drug
INCB054707 administered once daily orally with water without regard to food for 8 weeks.